Thailand’s Medical Cannabis Outlook In 2026
Separating Retail Headlines from Medical Export Reality
By Jamie L Pearson, Founder of New Holland Group
Thailand’s flip-flopping cannabis policy has caused whiplash and caution. Typical confusion centers on whether Thailand reversed legalization, and how that affects the medical export supply. The answer requires separating domestic retail policy from the licensed medical export framework, a distinction that media coverage continues to conflate.
In 2025, Thai authorities responded to rapid retail expansion with a predictable move. They clamped down. This led to a contraction of storefronts, and the contraction was huge. There were 18,433 registered cannabis establishments in Thailand as of December 2024. In 2025, 7,297 licensed cannabis shops closed. Authorities also conducted enforcement inspections, closing another 1,079 shops and seizing nearly one metric ton of cannabis. The retail market contraction left approximately 11,000 shops, meaning over 40% of legal retail stores in Thailand disappeared in 12 months.
Today, domestically, purchasing cannabis requires a medical prescription, flower is classified as a controlled herb, and retail operators face exhaustive reporting obligations. These new measures affect dispensaries, consumer access, and advertising practices. The bottom line for medical export is that medical licensed cultivation and export authorization rules remain, by and large, unaffected.
Due diligence note: Thailand still lacks a unified cannabis law. The Cannabis and Hemp Act has not passed parliament, leaving a hybrid framework combining the 2025 medical-use regulations with a layer of unrepealed directives issued between 2022 and 2024. Any renewal, ownership change, or relocation of a licensed operator triggers a full reassessment under 2025 clinic rules. For international buyers building supply relationships, that legal incompleteness is material, not a dealbreaker, but a necessary consideration.
Thailand’s Export Pathway
Thailand’s export-focused operators are required to maintain cultivation licenses, export permits, traceability systems, and agricultural compliance standards such as GACP alignment. The export framework remains operational under closer supervision. For medical buyers, the domestic retail policy turbulence has not resulted in export disruption.
Public trade data provides context, and Australia offers the most transparent “origin by weight” data. Thai-origin cannabis enjoys an undeniable presence in the Australian market. However, Australian import data must be read carefully in the 2025-2026 context. Australia’s Office of Drug Control confirmed that companies requested a combined 150 tons of import permits for 2025, but only half were actually imported. That difference prompted the INCB to formally reduce Australia’s national quota from 101 to 88 tons. It turns out, companies inflated forecasts to “lock up” quota capacity and distorted the data. Thai-origin volumes exist in the Australian market, but buyers should not treat aggregate Australian import statistics as a straightforward proxy for Thai export health.
Germany’s Federal Opium Agency (BfArM) also publishes import statistics, where Portugal and Canada still dominate. Thailand remains marginal in German statistics, partly explained by a practice worthy of being named explicitly: “GMP Washing”. Product leaves Thailand under GACP certification, moves to an EU-GMP processing intermediary in a third country, often the Netherlands, Portugal, the Czech Republic, Malta, or Germany itself, and re-enters supply chains labeled under that intermediary’s GMP origin. The underlying Thai cultivation is real and GACP-compliant; the EU-GMP processing step is also real. But the result is that Thai-origin material is systematically undercounted in country-of-origin statistics, and operators who describe themselves as “exporting to Germany” via this pathway are being technically accurate, while omitting a material detail that matters to buyers assessing origin-of-cultivation relationships.
The UK does not publish “origin by weight” breakdowns. Thai-origin products are referenced in trade coverage, but determining the quantities is difficult when these numbers are not reported.
Thailand should be viewed as a developing export origin with genuine structural advantages such as a favorable climate, very low production costs, and a growing cohort of outstanding operators.
That said, the field of credible export partners is narrower than headline numbers suggest. As of late 2025, just 149 farms hold GACP certification against more than 11,800 license holders. Diversifying origin risk remains standard procurement practice for serious buyers, and the demand for verified Thai supply is growing at a conservative rate, but the number of qualified suppliers is still quite limited.
The Competitive Pricing Reality
Thailand’s medical export ambitions do not exist in a vacuum. The global supply has become significantly more competitive since 2022, and buyers evaluating Thai-origin supply are simultaneously evaluating alternatives from Colombia, South Africa, Costa Rica, Morocco, and established EU-GMP producers from Canada and Portugal.
Per the Global Cannabis Exchange Spring 2025 Report, EU-GMP certified flower above 20% THC in Germany trades around €3.25 per gram. In Switzerland, a comparable product reaches approximately CHF 3.80 per gram. Australia has seen GACP flower drop to AUD $2.70 per gram, and UK GACP-certified flower can be sourced below £1.50 per gram. Colombian cultivation costs have been reported as low as $0.10 per gram, a cost structure that fundamentally changes the competitive landscape for flower-only export propositions. South Africa shipped over 8.5 tons in 2023 and is scaling rapidly. For Thai operators whose value proposition is “premium quality at lower cost than Canada or Portugal,” the emergence of Colombian and African supply at even lower cost is a strategic challenge that the Thai export field must answer with compliance credibility, financial flexibility, strain consistency, and finished-product excellence, not price alone.
The operators best positioned to compete in this environment are those who have already closed the gap to EU-GMP alignment, built finished-product OEM capability, established verified trade relationships with licensed importers, and demonstrated genetic consistency and phenotype stability across batches. Consistency and stability are crucial in medical markets.
The Licensing Cliff: 2026 and 2027
The 2025 retail closures have been widely documented. Less discussed is what comes next. An additional 4,587 licenses are set to expire in 2026, and a further 5,210 in 2027. Under the current hybrid regulatory framework, any renewal triggers full reassessment and a compliance standard that most domestic operators cannot meet. The practical result is continued consolidation of the operator landscape through 2027, further narrowing the field of credible supply partners. GACP-only operators compete in a crowded mid-tier. The differentiation is structural and significant.
For international buyers, this is a reason to engage exclusively with Thai operators who are already operating under the 2025 standards and hold current GACP certification. The license cliff reinforces the same conclusion the certification data already suggests: there are a handful of outstanding Thai export partners who offer a measurable advantage when establishing a secure supply. The range between “viable” and “could be viable” is a mile wide. A few examples of those who operate effectively in the Thai export market are featured below.
The Operator Landscape: Who Actually Has the Infrastructure
Thailand’s export-oriented operators present vastly varying levels of regulatory readiness and international positioning. The following analysis reflects publicly verifiable information drawn from corporate disclosures, observable export positioning, and available trade data. The competitive picture has sharpened considerably, and the distance between operators is not incremental. It is structural.
Iridescent Med is the clearest example of what Thailand’s medical export market can produce at its best. Operating out of GACP-certified, controlled-environment cultivation facilities in Chon Buri and Bang Pu, totaling more than 20,000 square meters, the company is also developing an EU-GMP post-harvest processing and packaging facility. The company has documented EU-GMP alignment, the combination that allows products to move into the EU’s regulated pharmaceutical channels with the lowest documentation friction of any Thai operator.
Iridescent Med has successfully shipped into both the EU and Australia, the two most demanding compliance jurisdictions for cannabis imports globally. They have publicly committed to doubling cultivation capacity and will achieve EU-GMP certification in 2026. Their Bang Pu facility produces over one metric ton annually, including specialized cannabinoids such as CBG and CBN. A strain library anchored by verified high-THC medical varieties, combined with a fully integrated OEM manufacturing capability for finished health and wellness products, produces a supply proposition that is genuinely competitive at the global level, not just regionally. For international buyers, Iridescent Med is the current reference benchmark for Thai-origin supply.
Cannex Pharma lists Japan, the UK, Germany, and Australia as target markets in corporate materials, with an export-oriented licensing model featuring brands like Cookies. Expected to have their GMP certification for manufacturing, extraction, and lab testing within the next year, the certification and export gap between what is stated and what is openly verifiable likely reflects their desire to work and grow quietly. By all accounts, Cannex Pharma is a high-quality operator to keep in mind.
Idol Farm — GACP-Certified, Early-Stage International
Idol Farm is a Bangkok-based medical cannabis operation that holds Thai GACP certification and has publicly positioned itself as an international export supplier. The farm operates under the GACP framework required for export eligibility. Idol Farm represents a growing category of Thai operations that have taken compliance seriously enough to invest in GACP certification.
Aran Therapeutics, Siam Cannabis Group, & Thai Genesis Trading
Aran Therapeutics, Siam Cannabis Group, and Thai Genesis Trading Co., Ltd all lack either verifiable international export profiles from available public data sources or verifiable evidence of GACP certification. Buyers should request GACP certification documentation, export permit history, and completed destination-market shipment records directly before treating either operator as procurement-ready. These operators are still very much active and working toward being medical suppliers.
World Pharma Solutions is publicly visible with GACP positioning and a described distribution infrastructure. The company occupies a mid-tier position in the Thai export landscape and is credentialed enough to warrant contact.
The Practical Takeaway for International Buyers
For executives and buyers attending the International Cannabis Business Conference, the practical guidance is straightforward. Thailand is a functioning medical export jurisdiction with real supply capability and growing international relevance. But the operator field is narrow. Out of more than 11,800 licensed cannabis-related operators in Thailand, 149 hold GACP certification. Of those, a very, very small subset has verifiable international export histories. Of that subset, Iridescent Med has documented EU-GMP alignment, confirmed trade activity into both the EU and Australia, and recognized international industry positioning with high-quality lifestyle branding. That is not marketing. It is a structural fact about the current Thai supply market.
Buyers should approach all operator claims with a request for evidence of rigorous documentation standards. Beyond cultivation quality, international buyers typically require full batch records, stability data, microbial testing, pesticide screening, and importer QA approval before entering procurement discussions. Export permits specifying destination countries, completed shipment records, and customs clearance documentation, and batch-specific Certificates of Analysis from shipments that have already crossed borders (not projections), are necessary evidence of compliance with destination-market standards, including any EU-GMP processing pathway details. Operators who can produce this documentation upon request would be considered procurement-ready. Cannabis buyers trust but verify.
The “GMP washing” dynamic described above is worth flagging in buyer-side diligence as well. When a Thai operator describes their product as “EU-GMP compliant” or “exported to Germany,” the question that follows, “Is the product moving under a Thai-origin EU-GMP manufacturing authorization, or is it entering an EU-GMP processing step at an intermediary in a third country before final market entry?” Both supply structures can be fully legal and legitimate. But they represent different risk profiles, different documentation chains, and different levels of Thailand’s actual presence in the destination market’s regulatory record.
The EU-GMP processing intermediary model is not necessarily problematic. In many cases, it is a required regulatory step, as many cultivation countries do not operate EU-GMP manufacturing facilities domestically. International buyers should also note that entry into EU medical markets requires a licensed importer and Qualified Person (QP) batch release within the destination jurisdiction. The import and export of medical cannabis is complex. The underlying idea, “buy low in Thailand, sell high in Europe,” works, but doing it well and keeping a good portion of the spread will boil down to many of the details outlined here.
Thailand’s cannabis policy narrative will remain politically dynamic for the foreseeable future. The absence of a unified Cannabis and Hemp Act, the pending license expiration waves in 2026 and 2027, and the political fragility of the post-Anutin government mean the regulatory floor is not yet settled. Export-focused operators with GACP certification, active export licenses, and documented international trade relationships are insulated from domestic retail volatility. While they are not fully insulated from legislative risk, buyers entering long-term supply agreements should include regulatory change provisions and documentation update requirements in contract terms.
The question as to whether Thailand can produce high-quality medical cannabis for export, the evidence answers that with a resounding, “Yes!” The better question is who in the Thai market has built the infrastructure substantial enough to sustain international supply commitments through the regulatory uncertainty ahead. That field is small and well-defined. Choose wisely.
***
This analysis is based on publicly verifiable information as of March 2026. It does not constitute legal or investment advice. Regulatory frameworks referenced are subject to change.
